Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252595 | 0.90 | ESR1 (0.54) | ESR1CYP19A1KMT2AMEN1HSPD1 | |
| SCHEMBL6255089 | 0.87 | MAPT (0.50) | ESR1CYP19A1KMT2AMEN1HSPD1 | |
| SCHEMBL8172861 | 0.81 | MAPT (0.62) | KMT2AMEN1PTPN2PTPN1PTPN5 | |
| SCHEMBL8544817 | 0.75 | GAA (0.53) | ESR1CYP19A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL8539408 | 0.74 | MAPT (0.49) | ESR1CYP19A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL8539179 | 0.74 | POLB (0.47) | ESR1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1415269 | 0.74 | MAPT (0.54) | KMT2AALDH1A1SMN1; SMN2LMNATHRB | |
| SCHEMBL22425029 | 0.72 | KMT2A (0.84) | ESR1CYP19A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL10586698 | 0.72 | MEN1 (0.61) | ESR1CYP19A1KMT2AMEN1HSPD1 | |
| SCHEMBL1415398 | 0.71 | MAPT (0.56) | SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0959881-B1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6750240-B2 | FORMING 2,5-DIHYDROXY-3,6-DI(2-(3-METHYL-N-BUTYL)INDOL-3-YL)-1,4-QUINONE BY REACTING 2,3,5,6-TETRABROMO-1,4-BENZOQUINONE WITH 2-(3-METHYL-N-BUTYL)INDOLE IN PRESENCE OF CESIUM CARBONATE; ANTICANCER AGENTS | SUGEN, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6660763-B2 | Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy | SUGEN, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030060635-A1 | Methods of using bis-indolylquinones | TANG PENG C (US) | 2003-03-27 | — | — | US | disclosed |
| US-20020156116-A1 | Bis-indolyquinone compounds | TANG PENG CHO (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1218342-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | Sugen, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6376529-B1 | INSULIN DISEASES; ANTIDIABETIC AGENTS | SUGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020016353-A1 | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN INC. | 2002-02-07 | — | — | US | disclosed |
| EP-0831809-A4 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN INC (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-0959881-A4 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6239161-B1 | 2,5-DIHYDROXY-3,6-DI-(INDOL-3-YL)-QUINONE DERIVATIVES; ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS | SUGEN, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| US-6110957-A | ANTITUMOR AGENT TREATING CELL PROLIFERATIVE DISORDERS SUCH AS CANCER, DYES, FUNGICIDES, BACTERICIDES | SUGEN, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6090838-A | USING 2,5-BISINDOL-3-YL-1,4-QUINONE | SUGEN, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0959881-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | Sugen, Inc. (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5780496-A | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020874-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0831809-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | Sugen, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040115-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156116-A1 | Bis-indolyquinone compounds | IRS1, GRK2, GID4 | ESR1 2687/4885CYP19A1 2594/4885KMT2A 2367/4885 |
| US-20030060635-A1 | Methods of using bis-indolylquinones | IDO2, IDO1, IPO5 | ESR1 4140/4885CYP19A1 426/4885KMT2A 1091/4885 |
| US-20020016353-A1 | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | GRB2, NCK1, ABL1 | ESR1 4194/4885CYP19A1 4870/4885KMT2A 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.